Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals IncfiledCriticalAgios Pharmaceuticals Inc
Priority claimed from PCT/US2018/000128external-prioritypatent/WO2019035864A1/en
Publication of MA49910B1publicationCriticalpatent/MA49910B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
L'invention concerne des composés qui activent la pyruvate kinase, des compositions pharmaceutiques et des procédés d'utilisation de ceux-ci. Ces composés sont représentés par la formule (i) dans laquelle r1, r2, ra, rb, rj, rk, et q sont tels que définis dans la description.The invention relates to compounds which activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by formula (i) in which r1, r2, ra, rb, rj, rk, and q are as defined in the description.
MA49910A2018-05-182018-08-15
Pyruvate kinase activators for use in the treatment of blood disorders
MA49910B1
(en)
1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders